The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / 2015 ACR/ARHP Annual Meeting: Stroke Risk Elevated after Herpes Zoster Infection Among Patients with Autoimmune Disease

2015 ACR/ARHP Annual Meeting: Stroke Risk Elevated after Herpes Zoster Infection Among Patients with Autoimmune Disease

February 16, 2016 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF
donskarpo/shutterstock.com

Image Credit: donskarpo/shutterstock.com

SAN FRANCISCO—The risk of stroke after herpes zoster (HZ) infection is elevated in the period immediately after infection in patients with autoimmune diseases, according to a study presented at the 2015 ACR/ARHP Annual Meeting.1

You Might Also Like
  • Herpes Zoster & the Risk of Stroke in Patients with Autoimmune Diseases
  • 2015 ACR/ARHP Annual Meeting: Role of Tumor Necrosis Factor Cytokines in Autoimmune Diseases Examined
  • 2015 ACR/ARHP Annual Meeting: T Follicular Helper Cells Emerge as Potential Treatment Target for Autoimmune Diseases
Explore This Issue
February 2016
Also By This Author
  • Early Consults, Timely Patient Histories Aid Rheumatologists Treating Patients in the ICU

The findings were presented in a scientific session, called Discover 2015, that highlighted new research. In another study from the session, researchers reported findings showing that intra-articular corticosteroids are safe and have no major effect on structural progression of synovitic knee osteoarthritis (OA).2

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Increased Stroke Risk

Dr. Calabrese

Dr. Calabrese

In the herpes zoster study, researchers from the Cleveland Clinic looked at Medicare data from 2006 through 2013, pulling data on patients with rheumatoid arthritis, inflammatory bowel disease, psoriatic arthritis, psoriasis and ankylosing spondylitis, said Leonard Calabrese, DO, head of the clinic’s Section of Clinical Immunology. To be included, subjects must not have had a previous stroke or a previous diagnosis of HZ or have taken an antiviral drug.

Researchers tracked patients after an HZ diagnosis, and the main outcome was hospitalized stroke.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

For all types of HZ, incidence of stroke was higher in the period right after the diagnosis, with 1.4 hospitalized strokes per 100 patient-years up to 30 days after diagnosis, and 1.2 in the second and third months after diagnosis. The stroke incidence continued to trail off after that.

Among those with serious or complicated HZ types—such as HZ of the cranial nerve or herpes zoster ophthalmicus—the difference was even more striking. The incidence within the first 30 days of diagnosis was 3.3 per 100 patient-years, and 1.8 in the second and third months, after which the incidence fell off.

The same pattern with respect to stroke and time from HZ diagnosis held true after adjustment for age, sex, diabetes, hypertension, atrial fibrillation, transient ischemic attack and glucocorticoid use.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Researchers found the incidence rate was higher among those who had not received anti-viral therapy within seven days of their HZ diagnosis. This was consistent with another publication, Dr. Calabrese said.3

“Immunosuppressed patients appear to be at an increased risk of stroke immediately after zoster, particularly in the first 30 days,” Dr. Calabrese said. He also said the data suggest that patients with immune-mediated diseases are under-protected because of a low rate of vaccination.

“They may be missing an additional downstream benefit of vaccination—subsequent reduction in stroke,” he said. “Collectively, on the basis of these data, we think that new strategies to optimize [the] prompt diagnosis and treatment [of], as well as preventive measures for, zoster are urgently needed.”

Intra-articular Corticosteroids & Knee OA

In the osteoarthritis study, researchers found no major effect of intra-articular corticosteroids on structural progress in knee OA patients. The therapy is widely used for knee pain in OA, but there is concern that it could accelerate damage to the knee. These findings might help ease those concerns.

The therapy has previously been found to be safe in the long term, but new technology—MRI, dual X-ray absorptiometry (DXA) and ultrasound—“offers [the] potential to scrutinize more carefully [the] structural effects of interventions,” said Timothy McAlindon, MD, MPH, chief of rheumatology at Tufts University.4

Intra-articular triamcinolone 40 mg every three months over two years into knees with synovitis has no major effect on structural measures either deleterious or beneficial. —Dr. McAlindon

Researchers randomized 140 knee OA patients—70 in each group—to receive injections of 40 mg of triamcinolone or saline every three months. Patients had to be at least 45 years old, with chronic knee pain and a WOMAC LK 3.1 pain subscore of at least 2.

Patients’ symptoms and self-reported function were assessed at each visit, with objective physical function tests given every six months. MRI and DXA imaging were done at 12 months and 24 months.

Researchers did find some difference in the cartilage damage index (CDI), with a drop in CDI of 0.84% in the saline group and a drop of 2.86% in the triamcinolone group. There was a drop in mean cartilage thickness of 0.57% in the saline group and of 1.7% in the triamcinolone group.

Dr. McAlindon

Dr. McAlindon

Dr. McAlindon noted that the difference, although significant in statistical terms, was not large.

“The relative differences are quite similar—about 1% difference in change between the two groups,” he said.

There were no statistical differences in the secondary outcomes of denudation, bone mineral loss, effusion volume and bone volume fraction.

“Intra-articular triamcinolone 40 mg every three months over two years into knees with synovitis has no major effect on structural measures either deleterious or beneficial. In particular, we found no evidence of accelerated progression,” Dr. McAlindon said. “Also, we found no influence on patient-reported outcomes or objective physical function tests over the long term.”


Thomas R. Collins is a medical writer based in Florida.

Second Chance

If you missed this session, it’s not too late. Catch it on SessionSelect

http://acrannualmeeting.org/resources/sessionselect

References

  1. Calabrese L, Xie F, Yun H, et al. Herpes zoster and the short term risk for ischemic stroke in patients with autoimmune diseases. Presented at the 2015 American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting. Nov. 6–11, 2015. Abstract 896.
  2. Driban J, Lavalley M, Price L, et al. Intra-articular corticosteroids are safe and have no major effect on structural progression of synovitic knee OA: A 2-year randomized controlled trial of 3-monthly triamcinolone hexacetonide. Presented at the 2015 American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting. Nov. 6–11, 2015. Abstract 897.
  3. Lin HC, Chien CW, Ho JD, et al. Herpes zoster ophthalmicus and the risk of stroke: A population-based follow-up study. Neurology. 2010 Mar 9;74(10):792–797.
  4. Raynauld JP, Buckland-Wright C, Ward R, et al. Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: A randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2003 Feb;48(2):370–377.

Pages: 1 2 3 | Multi-Page

Filed Under: Conditions, Meeting Reports Tagged With: 2015 ACR/ARHP Annual Meeting, American College of Rheumatology, Autoimmune disease, herpes, Infection, patient care, Research, risk, strokeIssue: February 2016

You Might Also Like:
  • Herpes Zoster & the Risk of Stroke in Patients with Autoimmune Diseases
  • 2015 ACR/ARHP Annual Meeting: Role of Tumor Necrosis Factor Cytokines in Autoimmune Diseases Examined
  • 2015 ACR/ARHP Annual Meeting: T Follicular Helper Cells Emerge as Potential Treatment Target for Autoimmune Diseases
  • 2015 ACR/ARHP Annual Meeting: Novel Approaches for Intra-Articular Arthritis Therapy

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.